CN1440295A - 含有作为活性剂的致免疫的酰基甘油基磷脂酰肌醇甘露低聚糖的疫苗 - Google Patents

含有作为活性剂的致免疫的酰基甘油基磷脂酰肌醇甘露低聚糖的疫苗 Download PDF

Info

Publication number
CN1440295A
CN1440295A CN01812245A CN01812245A CN1440295A CN 1440295 A CN1440295 A CN 1440295A CN 01812245 A CN01812245 A CN 01812245A CN 01812245 A CN01812245 A CN 01812245A CN 1440295 A CN1440295 A CN 1440295A
Authority
CN
China
Prior art keywords
pim
vaccine
immune
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01812245A
Other languages
English (en)
Chinese (zh)
Inventor
韦恩·布鲁斯·塞弗恩
格雷厄姆·斯蒂芬·勒格罗斯
雅基耶·露西尔·哈佩尔
保罗·亨利·阿特金森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agomasochi Co
University of Otago
Malaghan Institute of Medical Research
Original Assignee
Agomasochi Co
University of Otago
Malaghan Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomasochi Co, University of Otago, Malaghan Institute of Medical Research filed Critical Agomasochi Co
Publication of CN1440295A publication Critical patent/CN1440295A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN01812245A 2000-07-03 2001-07-02 含有作为活性剂的致免疫的酰基甘油基磷脂酰肌醇甘露低聚糖的疫苗 Pending CN1440295A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ505538A NZ505538A (en) 2000-07-03 2000-07-03 A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
NZ505538 2000-07-03

Publications (1)

Publication Number Publication Date
CN1440295A true CN1440295A (zh) 2003-09-03

Family

ID=19927977

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01812245A Pending CN1440295A (zh) 2000-07-03 2001-07-02 含有作为活性剂的致免疫的酰基甘油基磷脂酰肌醇甘露低聚糖的疫苗

Country Status (8)

Country Link
US (1) US20040022793A1 (enExample)
EP (1) EP1301203A4 (enExample)
JP (1) JP2004501980A (enExample)
CN (1) CN1440295A (enExample)
AU (1) AU2001280300A1 (enExample)
CA (1) CA2414347A1 (enExample)
NZ (1) NZ505538A (enExample)
WO (1) WO2002002140A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014367B (zh) * 2004-08-24 2012-07-04 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法
CN102626386A (zh) * 2012-04-28 2012-08-08 山东大学 一种卡介菌多糖核酸吸入气雾剂、制备方法及用途
US10118959B2 (en) 2005-10-14 2018-11-06 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
CN113663065A (zh) * 2020-05-15 2021-11-19 山东大学 一种肌醇甘露寡糖缀合物、制备方法及作为抗结核糖疫苗的应用
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
CN118178640A (zh) * 2024-03-08 2024-06-14 中国农业大学 含有牛分枝杆菌表面多糖的佐剂及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005532A2 (en) * 2002-07-10 2004-01-15 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
WO2005049631A1 (en) * 2003-11-18 2005-06-02 The Malaghan Institute Of Medical Research Synthetic molecules having immune activity
WO2007142510A1 (en) * 2006-06-09 2007-12-13 Erasmus University Medical Center Rotterdam Modulation of the immune system by inositol phospholipids
EP2139501B1 (en) 2007-03-21 2016-04-13 National Research Council of Canada Use of francisella tularensis for prevention and treatment of allergic airway disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS568320A (en) * 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
FR2596651B1 (fr) * 1986-04-08 1989-11-10 Centre Nat Rech Scient Nouveaux liposomes a base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
US5853737A (en) * 1992-12-10 1998-12-29 Brigham And Women's Hospital Method for inducing a CD1-restricted immune response
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
US6238676B1 (en) * 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
GB2316323B (en) * 1996-06-20 1999-09-22 Aid Medic Ltd Dispensing system
FR2792205B1 (fr) * 1999-04-19 2001-07-27 Inst Nat Sante Rech Med Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014367B (zh) * 2004-08-24 2012-07-04 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法
CN102698267A (zh) * 2004-08-24 2012-10-03 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法
CN102698267B (zh) * 2004-08-24 2017-07-21 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法
US10118959B2 (en) 2005-10-14 2018-11-06 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody
CN102626386A (zh) * 2012-04-28 2012-08-08 山东大学 一种卡介菌多糖核酸吸入气雾剂、制备方法及用途
CN102626386B (zh) * 2012-04-28 2014-10-29 山东大学 一种卡介菌多糖核酸吸入气雾剂、制备方法及用途
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
CN113663065A (zh) * 2020-05-15 2021-11-19 山东大学 一种肌醇甘露寡糖缀合物、制备方法及作为抗结核糖疫苗的应用
CN113663065B (zh) * 2020-05-15 2024-01-16 山东大学 一种肌醇甘露寡糖缀合物、制备方法及作为抗结核糖疫苗的应用
CN118178640A (zh) * 2024-03-08 2024-06-14 中国农业大学 含有牛分枝杆菌表面多糖的佐剂及其应用

Also Published As

Publication number Publication date
WO2002002140A1 (en) 2002-01-10
EP1301203A4 (en) 2004-07-21
CA2414347A1 (en) 2002-01-10
JP2004501980A (ja) 2004-01-22
US20040022793A1 (en) 2004-02-05
EP1301203A1 (en) 2003-04-16
AU2001280300A1 (en) 2002-01-14
NZ505538A (en) 2004-12-24

Similar Documents

Publication Publication Date Title
JP4648955B2 (ja) 生物材料およびその使用
CN1440295A (zh) 含有作为活性剂的致免疫的酰基甘油基磷脂酰肌醇甘露低聚糖的疫苗
EP1461054B1 (en) Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
AU2002215123A1 (en) M. tuberculosis chaperonin 10 and uses thereof
JP5801868B2 (ja) 解毒した大腸菌易熱性エンテロトキシンを用いたアレルギー治療法
AU779163B2 (en) Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
Onah et al. Mucosal mast cell-derived chondroitin sulphate levels in and worm expulsion from FcRgamma-knockout mice following oral challenge with Strongyloides venezuelensis
WO2021158990A1 (en) Therapeutic fractions and proteins from asthma-protective farm dust
Srivastava et al. Proteolytically inactive per a 10 allergen of Periplaneta americana modulates Th2 response and enhances IL-10 in mouse model
Mousavi et al. Study of Chenopodium album allergenic extract to induce allergic asthma in murine model
Stock et al. Recent advances in the role of NKT cells in allergic diseases and asthma
US20230026406A1 (en) Therapeutic fractions and proteins from asthma-protective farm dust
KR100350864B1 (ko) 신규 당단백질, 그 정제방법 및 이를 포함하는 항알러지조성물
EP1764369A1 (de) Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
RU2772735C1 (ru) Способ профилактики или терапии острого респираторного дистресс-синдрома на модели индуцированного ОРДС у лабораторных животных
CA2367447A1 (en) Treatment of asthma
US20040247622A1 (en) Methods and compounds for the treatment of immunologically-mediated diseases using Mycobacterium vaccae
Fink Fungal allergy: from asthma to alveolitis
Yang Effect of Trichinella spiralis intervention on Citrobacter rodentium-induced experimental colitis in mice
CN1491723A (zh) 用于治疗过敏性疾病的药物及其制备方法
Major The influence of infections on the development of allergic disorders
Pitt et al. lymphoid tissue of various strains of mice
Tulic et al. LPS stimulates T cell proliferation and expression of IL-10 in the nasal mucosa of young atopic children but not in atopic adults
CN1194833A (zh) 肺活素
HK1067073B (en) Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication